Efficacy and Tolerability of Metamizol in Patients With Episodic Moderate Headache
Primary Purpose
Migraine Disorders
Status
Completed
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
Metamizol
Acetylsalicylic acid (ASA)
Metamizol placebo
ASA placebo
Sponsored by
About this trial
This is an interventional treatment trial for Migraine Disorders
Eligibility Criteria
Inclusion Criteria:
- Male and female patients between 18 and 65 years old
- Moderate episodic tension headache according to International Headache Society (I.H.S.) classification 2.1 (2.1.1 and 2.1.2) for at least one year
- At least two episodes of tension headache per month in the last three months prior to enrolment into this trial
- The episodes of tension headaches were usually treated by the patient successfully with a non-opioid-analgesic
- First episodic headache occurred at an age under 50 years
- Written informed consent according to Good Clinical Practice (GCP) and local regulations
- The patient was able to fill in the Patient's Diary
Exclusion Criteria:
- The patient usually needs for successful treatment of tension headache "Over The Counter" (OTC) analgesic in doses exceeding the doses tested here
- The patient takes an OTC-analgesic normally at the first signs of an episode of tension headache
- The patient has more than 15 episodes of tension headache per month
- Female patients whose episodic tension headache is strongly correlated with the start of hormonal contraception
- Concomitant treatment with (non-) prescriptional analgesics
- Pre- (less than 4 weeks prior to inclusion in this trial) and/or concomitant treatment with an antidepressive and/or antipsychotic drug
- Pre- (less than 2 weeks prior to inclusion in this trial) and/or concomitant treatment with any drug such as NSAIDs (Non-Steroidal Anti Inflammatory Drugs), propanolol, metroprolol, flunarizin, cyclandelate, valproic-acid, serotonergic antagonists, ergotamine, dihydroergotamines and benzodiazepines that may influence the headache symptomatology
- Use of benzodiazepines in the previous 24 hours to the administration of the study drug. Occasional use of benzodiazepines - up to 3 per week - is allowed
- Use of any drug with analgesic properties in the previous 24 hours to the administration of the study drug
- Concomitant treatment with any drug containing ASA and/or metamizol
- Concomitant treatment with anticoagulants such as heparin or coumarin-derivatives
- Alcohol and drug abuse according to DSM-IV (Diagnostic and Statistical Manual of Mental Disorders )
- Female patients in child-bearing age not using adequate means of birth control
- Pregnancy and/or lactation
- Gastrointestinal ulcers
- Liver and/or renal disease
- Bronchial asthma
- Relevant allergy or known hypersensitivity to the investigational drugs, its excipients and/or to other NSAIDs
- Participation in another clinical trial within the last 4 weeks and concurrent participation in another clinical trial
- Patients with active gastroesophageal flux disease (Amendment number 1)
- Concomitant treatment with analgesics or any other drug that may have influenced the headache symptomatology - including metamizol or ASA -, was referred to its use during the headache episodes under evaluation. As long as appropriate wash-out periods were respected, analgesics were allowed in between the episodes of tension headache (TH) and their use as a rescue medication did not lead to the exclusion of the patient (Amendment number 2)
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Active Comparator
Placebo Comparator
Arm Label
Metamizol high & Placebo
Metamizol low & Placebo
Acetylsalicylic acid & Placebo
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Time-interval weighted sum of pain intensity difference (SPID) on a Visual Analogue Scale (VAS)
Secondary Outcome Measures
Pain intensity difference (PID) on a VAS
Maximum pain intensity difference (MAXPID) on a VAS
Number of patients with at least a 50% pain reduction on a VAS
Time to 50% pain intensity reduction on a VAS
Maximum pain relief (MAXPAR) on a Verbal Rating Scale (VRS)
Total pain relief (TOTPAR) on a VRS
Number of patients using rescue medication
Global efficacy assessment on a VRS by the patient and investigator
Number of patients with adverse events
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT02183220
Brief Title
Efficacy and Tolerability of Metamizol in Patients With Episodic Moderate Headache
Official Title
A Randomised, Double Blind, Placebo- and Active-controlled Parallel Group Study Investigating the Efficacy and Tolerability of Metamizol 0.5 g and 1.0 g in Patients With Episodic Moderate Tension Headache.
Study Type
Interventional
2. Study Status
Record Verification Date
July 2014
Overall Recruitment Status
Completed
Study Start Date
October 1998 (undefined)
Primary Completion Date
July 1999 (Actual)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Boehringer Ingelheim
4. Oversight
5. Study Description
Brief Summary
The objective of the study was to evaluate the efficacy, safety and tolerability of a single peroral dose of 0.5 g and 1.0 g metamizol relative to placebo and 1.0 g acetylsalicylic acid in 2 episodes of moderate tension headache.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Migraine Disorders
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
417 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Metamizol high & Placebo
Arm Type
Experimental
Arm Title
Metamizol low & Placebo
Arm Type
Experimental
Arm Title
Acetylsalicylic acid & Placebo
Arm Type
Active Comparator
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Metamizol
Intervention Type
Drug
Intervention Name(s)
Acetylsalicylic acid (ASA)
Intervention Type
Drug
Intervention Name(s)
Metamizol placebo
Intervention Type
Drug
Intervention Name(s)
ASA placebo
Primary Outcome Measure Information:
Title
Time-interval weighted sum of pain intensity difference (SPID) on a Visual Analogue Scale (VAS)
Time Frame
before and 30 minutes, 1, 2, 3, and 4 hours after drug intake
Secondary Outcome Measure Information:
Title
Pain intensity difference (PID) on a VAS
Time Frame
before and 30 minutes, 1, 2, 3, and 4 hours after drug intake
Title
Maximum pain intensity difference (MAXPID) on a VAS
Time Frame
before and 30 minutes, 1, 2, 3, and 4 hours after drug intake
Title
Number of patients with at least a 50% pain reduction on a VAS
Time Frame
before and 30 minutes, 1, 2, 3, and 4 hours after drug intake
Title
Time to 50% pain intensity reduction on a VAS
Time Frame
before and 30 minutes, 1, 2, 3, and 4 hours after drug intake
Title
Maximum pain relief (MAXPAR) on a Verbal Rating Scale (VRS)
Time Frame
30 minutes, 1, 2, 3, and 4 hours after drug intake
Title
Total pain relief (TOTPAR) on a VRS
Time Frame
30 minutes, 1, 2, 3, and 4 hours after drug intake
Title
Number of patients using rescue medication
Time Frame
2, 3, and 4 hours after drug intake
Title
Global efficacy assessment on a VRS by the patient and investigator
Time Frame
4 hours after drug intake
Title
Number of patients with adverse events
Time Frame
up to 2 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male and female patients between 18 and 65 years old
Moderate episodic tension headache according to International Headache Society (I.H.S.) classification 2.1 (2.1.1 and 2.1.2) for at least one year
At least two episodes of tension headache per month in the last three months prior to enrolment into this trial
The episodes of tension headaches were usually treated by the patient successfully with a non-opioid-analgesic
First episodic headache occurred at an age under 50 years
Written informed consent according to Good Clinical Practice (GCP) and local regulations
The patient was able to fill in the Patient's Diary
Exclusion Criteria:
The patient usually needs for successful treatment of tension headache "Over The Counter" (OTC) analgesic in doses exceeding the doses tested here
The patient takes an OTC-analgesic normally at the first signs of an episode of tension headache
The patient has more than 15 episodes of tension headache per month
Female patients whose episodic tension headache is strongly correlated with the start of hormonal contraception
Concomitant treatment with (non-) prescriptional analgesics
Pre- (less than 4 weeks prior to inclusion in this trial) and/or concomitant treatment with an antidepressive and/or antipsychotic drug
Pre- (less than 2 weeks prior to inclusion in this trial) and/or concomitant treatment with any drug such as NSAIDs (Non-Steroidal Anti Inflammatory Drugs), propanolol, metroprolol, flunarizin, cyclandelate, valproic-acid, serotonergic antagonists, ergotamine, dihydroergotamines and benzodiazepines that may influence the headache symptomatology
Use of benzodiazepines in the previous 24 hours to the administration of the study drug. Occasional use of benzodiazepines - up to 3 per week - is allowed
Use of any drug with analgesic properties in the previous 24 hours to the administration of the study drug
Concomitant treatment with any drug containing ASA and/or metamizol
Concomitant treatment with anticoagulants such as heparin or coumarin-derivatives
Alcohol and drug abuse according to DSM-IV (Diagnostic and Statistical Manual of Mental Disorders )
Female patients in child-bearing age not using adequate means of birth control
Pregnancy and/or lactation
Gastrointestinal ulcers
Liver and/or renal disease
Bronchial asthma
Relevant allergy or known hypersensitivity to the investigational drugs, its excipients and/or to other NSAIDs
Participation in another clinical trial within the last 4 weeks and concurrent participation in another clinical trial
Patients with active gastroesophageal flux disease (Amendment number 1)
Concomitant treatment with analgesics or any other drug that may have influenced the headache symptomatology - including metamizol or ASA -, was referred to its use during the headache episodes under evaluation. As long as appropriate wash-out periods were respected, analgesics were allowed in between the episodes of tension headache (TH) and their use as a rescue medication did not lead to the exclusion of the patient (Amendment number 2)
12. IPD Sharing Statement
Links:
URL
http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1093/1093.16_U00-0018.pdf
Description
Related Info
Learn more about this trial
Efficacy and Tolerability of Metamizol in Patients With Episodic Moderate Headache
We'll reach out to this number within 24 hrs